NIH and Federal Grant Funding: The Opportunity Most Companies Get Right, and the Compliance Burden Most Get Wrong
For an early-stage life sciences or biotech company, an NIH grant or SBIR/STTR award can be transformative. It's non-dilutive capital — money that doesn't cost you equity, doesn't require giving up a board seat, and signals real validation to future investors. For many founders, it's the funding that gets the science far enough to make the next round possible at all.
But here's what rarely gets said out loud: the moment you accept that funding, you've taken on an obligation, not just a credit to your bank account. And that obligation is one most growth-stage finance functions aren't built to handle.
The Opportunity Is Real
It's worth pausing on why this funding matters before getting into the compliance side, because the upside is genuine. Federal grant funding lets you advance research and development without diluting ownership — capital that would otherwise come from investors who want a percentage of your company in return. It often arrives earlier than venture capital is willing to, covering exactly the stage where the science is too early for most institutional investors but too expensive to fund out of pocket. And a federal award carries a credibility signal: NIH and federal agencies have already vetted the science, which future investors notice.
For the right company, this funding doesn't just extend runway — it changes the trajectory of what's possible.
What Changes the Day the Money Arrives
The mistake many companies make is treating a federal grant like a deposit — money that's now simply available to spend against the budget. It isn't. From the day of the award, the company has accepted a set of financial reporting and compliance obligations that run in parallel with the science, and those obligations are unforgiving of being an afterthought.
A few examples of what this actually involves, drawn from real grant administration work:
Federal Financial Reports (FFRs) must be filed on strict schedules, reconciled precisely against drawn funds — not estimated, not approximated.
Research Performance Progress Reports (RPPRs) tie financial reporting to scientific progress, and the two need to be consistent with each other.
Drawdown reconciliation through the Payment Management System (PMS) has to match actual expenditures, not just available balances — a mismatch here can trigger scrutiny that slows everything down.
SAM.gov registration must stay current and accurate, or it can quietly jeopardize a company's eligibility to draw down funds it has already been awarded.
eRA Commons filings, invention reporting through iEdison, and foreign disclosure requirements all carry their own deadlines and their own consequences for being late or incomplete.
Prior approval requirements — for things like late liquidation of funds, or changes to how money is being spent — have to be requested before the action, not justified after the fact.
None of this is optional, and none of it forgives "we'll catch up on it later." A missed FFR deadline or an unreconciled drawdown doesn't just create paperwork — it can delay future draws, trigger additional agency scrutiny, or in serious cases put the award itself at risk.
Where This Usually Breaks Down
Most growth-stage companies don't have a finance function built for this. A bookkeeper or controller who's excellent at standard monthly close has often never seen a PMS drawdown screen or an RPPR. The company's existing financial processes were built for running a business, not for satisfying a federal agency's specific and exacting reporting requirements — and the gap between those two things tends to surface at the worst possible time: right before a deadline, or right after a small error has already compounded.
This is also where the funding's benefit can quietly erode. Staff time gets pulled into compliance firefighting instead of the research the grant was meant to fund. Compliance gaps create friction with program officers. In the most serious cases, repeated issues can affect a company's standing for future awards — turning what should be a competitive advantage into a liability.
What Good Compliance Actually Looks Like
Done right, federal grant compliance isn't a once-a-quarter scramble — it's built into the company's ongoing financial operations from the start. That means reconciliation workbooks that track drawdowns against expenditures in real time, calendars that flag FFR and RPPR deadlines well before they're due, and a clear line of sight between the science team's progress and the finance team's reporting.
It also means someone on the team actually understands the federal grant ecosystem — PMS, eRA Commons, SAM.gov — well enough to catch a problem before it becomes a filing failure, not after.
Where This Leaves You
If your company has federal grant funding — or is pursuing it — the financial infrastructure to manage it well is not the same thing as the financial infrastructure to run daily operations. Both matter, but they require different expertise, and treating grant compliance as a side task for an already-stretched bookkeeper is one of the more common and most costly mistakes growth-stage companies make.
I built Helix Accounting's grant compliance work around exactly this gap — hands-on management of NIH and federal grant financial requirements, integrated with the rest of a company's financial operations rather than bolted on as an afterthought.
If your company has federal funding and you're not fully confident in how the compliance side is being managed, or you are considering such funding, I'd welcome the conversation.